A survey involving 120 small-scale dairy farmers was carried out to assess risk factors associated with brucellosis in cattle from selected sectors of Nyagatare District, Rwanda. A sample of cattle from nine selected sectors of Nyagatare was tested for brucellosis using the Rose Bengal Test. Of the respondents, 57.5% were unaware of brucellosis as a disease, 85.8% did not screen new additions to the herd for brucellosis and 82.5% did not remove brucellosis seropositive animals from the herd. The prevalence of brucellosis in herds with cows with no history of abortion was 38.5% and 17.0% in those with a history of abortion. None of the respondents disinfected abortion sites or vaccinated against brucellosis. The prevalence of brucellosis in cows with a history of retained placenta was 36% and 2% in those with no history of retained placenta. Of the respondents, 62.5% reportedly fed foetal membranes to dogs. About 65.8% of the respondents with brucellosis-positive animals reported a calving interval longer than 1 year. Katabagemu (28.6%) had the highest prevalence of brucellosis seropositivity while Karama had none. Brucellosis in cows (21.4%) was significantly higher than that in heifers (12.8%) (p < 0.05), but there was no significant difference between heifers and bulls or between bulls and cows (p > 0.05). The occurrence of brucellosis in herds with 40–70 cattle (26.9%) was significantly greater than the 14.9% of herds with 10–39 cattle (p < 0.05). Seropositivity to brucellosis in cross-breed cattle (23.6%) was significantly greater than that in indigenous cattle (13.8%) (p < 0.05). There was no significant difference in the overall prevalence of brucellosis in cattle from different grazing systems (p > 0.05). Seropositivity to brucellosis was significantly different (p < 0.05) between the fourth parity (32.5%) and first parity (14.3%) cows. The findings in this study confirmed the existence of brucellosis as a problem in Nyagatare and the authors recommend that farmer education on the epidemiology, risk factors and mitigation of the disease be undertaken as a matter of urgency.
This study investigated the overall prevalence of Haemonchus contortus infection in sheep and goats from five purposively selected subdivisions (sectors) of Nyagatare district from January to December 2014, after a high prevalence of gastrointestinal parasites and generalized poor productivity was reported in small ruminants in some districts of Rwanda. Faecal egg counts (FEC) were performed using the Modified Wisconsin Sugar Floatation method and the Fluorescent-labeled peanut-lectin agglutination test while enumerations, as log (FEC), were done using the modified McMaster method. The overall prevalence of H. contortus infection in sheep and goats was 75.7% (n=949). The overall prevalence of H. contortus infection in sheep (83.4%, n=314) was higher than in goats (71.8%, n=635) (Odds Ratio [OR] 1.98, 95% Confidence Interval [CI]: 1.40-2.79, and p≤0.001). The prevalence of H. contortus infection in female goats (74.2%) was higher than in male goats (64.3%) (OR 1.60, 95% CI: 1.09-2.36, and p=0.01). The prevalence of H. contortus infection in goats from Nyagatare was higher than in goats from Matimba (OR 3.25, 95% CI: 1.76-5.99, and p≤0.001) and from Katabagemu (OR 3.67, 95% CI: 2.04-6.59, and p≤0.001). The prevalence of H. contortus infection in goats from Karangazi was higher than in goats from Matimba (OR 4.72, 95% CI: 2.40-9.28, and p≤0.001). The overall mean monthly log (FEC) for H. contortus in sheep and goats were highest in April (18.9±0.2 and 14.05±0.1, respectively) and October (19.25± 0.2 and 13.75±0.1, respectively). Though, overall, sheep in Nyagatare district were at greater risk of H. contortus infection and goats from Nyagatare and Karangazi sectors were paradoxically at greater risk of H. contortus infection. It was also apparent that young female goats were at greater risk of H. contortus infection than young male goats. H. contortus infection is endemic in small ruminants in Nyagatare district and possibly other districts in Rwanda. Targeted selective treatment (TST) using FAMACHA with emphasis on low-lying swampy pastures and appropriate anthelmintic drugs may be the most economically viable solution in the short term. In the long term breeding of H. contortus resistant small ruminants and strategic grazing using the concept of refugia may bring about considerable relief from H. contortus infection in Nyagatare district, in particular, and Rwanda at large.
Four subclinical mastitis diagnostic tests (the UdderCheck® test [a lactate dehydrogenase-based test], the California Mastitis Test [CMT], the Draminski® test [a conductivity-based test] and the PortaSCC® test [a portable somatic cell count-based test]) were compared in a study comprising crossbreed dairy cows (n = 30) during September and October 2015. Sensitivity and specificity of the CMT, Draminski® and UdderCheck® tests were compared with the PortaSCC® as reference. The CMT, Draminski® and UdderCheck® test results were compared with the results of the PortaSCC® test using kappa statistics. Duplicate quarter milk samples (n = 120) were concurrently subjected to the four tests. Sensitivity and specificity were 88.46% and 86.17% (CMT), 78.5% and 81.4% (Draminski®) and 64.00% and 78.95% (UdderCheck®). The CMT showed substantial agreement (k = 0.66), the Draminski® test showed moderate agreement (k = 0.48) and the UdderCheck® test showed fair agreement (k = 0.37) with the PortaSCC® test and positive likelihood ratios were 6.40, 4.15 and 3.04, respectively. The cow-level subclinical mastitis prevalence was 70%, 60%, 60% and 56.7% for PortaSCC®, CMT, Draminski® and UdderCheck® tests, respectively. At udder quarter level, subclinical mastitis prevalence was 20%, 21.67% and 20.83% for PortaSCC®, CMT and UdderCheck®, respectively. A correlation (P < 0.05) and moderate strength of association were found between the four tests used. The study showed that compared to the PortaSCC® test, the CMT was the most preferable option, followed by the Draminski® test, while the UdderCheck® test was the least preferable option for subclinical mastitis screening.
This study was designed to investigate the cytotoxicity and haemotoxicity of the Western barred (zebra) spitting cobra (Naja nigricincta nigricincta) venom to help explain atypical and inconsistent reports on syndromes by Namibian physicians treating victims of human ophidian accidents. Freeze-dried venom milked from adult zebra snakes was dissolved in phosphate buffered saline (PBS) for use in this study. Haemorrhagic and necrotic activity of venom were studied in New Zealand albino rabbits. Oedema-forming activity was investigated in 10-day-old Cobb500 broiler chicks. Procoagulant and thrombolytic activity was investigated in adult Kalahari red goat blood in vitro. The rabbit skin minimum hemorrhagic dose (MHD) for N. n. nigricincta was 9.8μg. The minimum necrotizing dose (MND) for N. n. nigricincta venom was 12.2μg. The N. n. nigricincta venom showed linear dose-dependent procoagulant activity on goat blood (p<0.05). Likewise, N. n. nigricincta venom showed linear dose-dependent thrombolytic activity on goat blood (p<0.05, n = 6). Subplantar injection of N. n. nigricincta venom (25μg, 50μg, 75μg, and 100μg) into chick paw resulted in peak oedema of 35.5%, 38.5%, 42.9%, and 47.5%, respectively, two hours after injection. Paw oedema subsided within five hours to a mean volume ranging from 5% (25μg venom) to 17.6% (100μg venom). In conclusion, though N. n. nigricincta belongs to the genus Elapidae, the current study has shown its venom to possess potent hemorrhagic, necrotic (cytotoxic), and paradoxically, both procoagulant and thrombolytic activity. The authors propose further work to fractionate, isolate, and elucidate the structure of the various N. n. nigricincta venom toxins as a prelude to the development of an antivenom.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.